On May 8, 2020, AbbVie announced it had completed its acquisition of Allergan following receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court.

Allergan shareholders received 0.8660 AbbVie shares and $120.30 in cash for each Allergan share, for a total consideration of $193.23 per Allergan share or nearly $62 billion.